Martínez José A, Aguilar Josefa, Almela Manel, Marco Francesc, Soriano Alex, López Fina, Balasso Valentina, Pozo Laura, Mensa Josep
Department of Infectious Diseases, Hospital Clínic, IDIBAPS-University of Barcelona, Barcelona, Spain.
J Antimicrob Chemother. 2006 Nov;58(5):1082-5. doi: 10.1093/jac/dkl367. Epub 2006 Sep 1.
The increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae will probably trigger a rise in the use of carbapenems. The effect of these antibiotics on the risk of involvement of ESBL-producing organisms in serious infections is unclear.
Retrospective analysis of 2172 episodes of healthcare-associated bacteraemia diagnosed during a 3 year period in a teaching hospital. Putative risk factors included demographics, co-morbidities, previous isolation of an ESBL-producing organism and exposure to antibiotics. Univariate and multivariate analysis of the association of risk factors with ESBL-producing organisms was performed in the entire series of bacteraemic episodes and in those due to Escherichia coli or Klebsiella spp.
In the entire series, prior isolation of an ESBL-producing organism [odds ratio (OR) 5.9 (3.02, 11.5)]; an ultimately/finally fatal co-morbidity [OR 2.8 (1.55, 4.95)]; renal transplantation [OR 4.3 (1.96, 9.63)]; a urinary source [OR 4.2 (2.22, 7.84)]; shock [OR 2.4 (1.35, 4.1)] and previous use of cephalosporins [OR 2.6 (1.54, 4.51)], carbapenems [OR 2.5 (1.24, 5.05)] and glycopeptides [OR 0.4 (0.13, 0.93)] were significantly associated with ESBL-producing E. coli or Klebsiella spp. by multivariate analysis. Prior isolation of an ESBL-producing organism, an ultimately/finally fatal co-morbidity, renal transplantation, and previous use of cephalosporins and carbapenems were also significant in the analysis restricted to episodes due to E. coli or Klebsiella spp.
In patients with healthcare-associated bacteraemia, prior use of carbapenems may be only second to cephalosporins as the most significant antibiotic exposure associated with the involvement of ESBL-producing organisms.
产超广谱β-内酰胺酶(ESBL)肠杆菌科细菌的患病率不断上升,可能会引发碳青霉烯类药物使用的增加。这些抗生素对产ESBL生物引起严重感染风险的影响尚不清楚。
对一家教学医院3年内诊断的2172例医疗保健相关菌血症病例进行回顾性分析。假定的风险因素包括人口统计学特征、合并症、先前分离出产ESBL的生物以及接触抗生素情况。在整个菌血症病例系列以及由大肠杆菌或克雷伯菌属引起的病例中,对风险因素与产ESBL生物之间的关联进行单因素和多因素分析。
在整个系列中,多因素分析显示,先前分离出产ESBL的生物[比值比(OR)5.9(3.02,11.5)];最终/最后致命的合并症[OR 2.8(1.55,4.95)];肾移植[OR 4.3(1.96,9.63)];泌尿道感染源[OR 4.2(2.22,7.84)];休克[OR 2.4(1.35,4.1)]以及先前使用头孢菌素[OR 2.6(1.54,4.51)]、碳青霉烯类药物[OR 2.5(1.24,5.05)]和糖肽类药物[OR 0.4(0.13,0.93)]与产ESBL的大肠杆菌或克雷伯菌属显著相关。在仅限于由大肠杆菌或克雷伯菌属引起的病例分析中,先前分离出产ESBL的生物、最终/最后致命的合并症、肾移植以及先前使用头孢菌素和碳青霉烯类药物也具有显著性。
在医疗保健相关菌血症患者中,先前使用碳青霉烯类药物可能仅次于头孢菌素,是与产ESBL生物感染相关的最显著抗生素暴露因素。